Rezdiffra FDA approval fuels sales; expansion to F4 MASH cirrhosis with 2027 trial data. Read more about MDGL stock here.

Altimmune ALT announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide ...

Viking Therapeutics, Inc. stock has spiked over 200% this year after positive obesity data from its Phase 2 clinical study of drug candidate VK2735, a GLP-1 agonist, in weight loss. Viking stock has ...

CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...

CONSHOHOCKEN, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic ...

A Boehringer Ingelheim drug in development for weight loss now has data from a separate mid-stage clinical trial showing dramatic reductions across several measures of a fatty liver disease whose ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Survodutide improved metabolic dysfunction-associated ...

Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

Longer treatment with an Akero Therapeutics drug in development for the liver disease MASH led to better results, including improvement in fibrosis, the liver scarring that is a hallmark of the ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated molecules addressing serious liver diseases, today announced additional ...